A major focus of Dr Shaw’s research is on standardization and analytical qualification of methods to measure Alzheimer’s and Parkinson’s Disease biomarkers in biofluid samples, and determination of their clinical utilities, to support their successful use in clinical studies and treatment trials.  To that end he has led or participated in intercenter studies that have included biomarker scientists from academic and industrial laboratories to validate analytical performance of AD and PD biomarker measurements including immunoassay and mass spectrometry methods.  Integral to highly standardized biomarker measurements is the quality of the biofluid samples utilized and Dr Shaw has participated in the development of international guidelines for standardization of biofluid collection and storage procedures.  These studies and guidelines have provided the basis for the analytical methods and biofluid sample collection and management in use in Dr Shaw’s laboratory.  Dr Shaw co-directs the ADNI Biomarker Core and is a leader in the Bioanalytics Core of the PPMI study.